Market capitalization | $673.04m |
Enterprise Value | $392.23m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 73.04 |
P/S ratio (TTM) P/S ratio | 125.33 |
P/B ratio (TTM) P/B ratio | 1.98 |
Revenue growth (TTM) Revenue growth | 480.74% |
Revenue (TTM) Revenue | $5.37m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
12 Analysts have issued a Magenta Therapeutics Inc forecast:
12 Analysts have issued a Magenta Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 5.37 5.37 |
484%
484%
|
|
Gross Profit | 4.93 4.93 |
422%
422%
|
|
EBITDA | -82 -82 |
51%
51%
|
EBIT (Operating Income) EBIT | -83 -83 |
45%
45%
|
Net Profit | -67 -67 |
0%
0%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Marino Garcia |
Employees | 53 |
Founded | 2015 |
Website | dianthustx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.